MEI Pharma shares crash as cancer drug fails mid-stage test

March 23, 2015 11:31 AM

5 0

(Reuters) - MEI Pharma was set to lose more than half its market value on Monday after the company's cancer drug failed to meet the main goal in a mid-stage study.

The drug, pracinostat, was being tested in combination with chemotherapy drug azacitidine to treat patients with myelodysplastic syndrome - a type of blood cancer.

Also read: McDonald’s Revenue Tops Estimates as Breakfast Boosts U.S

Read more

To category page